Cardinal Health, Inc. (CAH) Stock Price & Analysis
Cardinal Health, Inc. (CAH) closed at USD 255.64 on Thursday, October 22, 2026, down 0.71% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 257.46; the Oct 22, 2026 session ranged USD 254.85–259.21 on volume of 1,497,509 shares. Market capitalization is $59.20B, with a 52-week range of USD 158.7–259.21 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CAH.md
Key facts (CAH)
- Last four reported quarters (through Dec 31, 2025): revenue $245B, net income $1.66B (0.7% margin), free cash flow $5.50B (SEC filings).
- Valuation: P/E 35.6x (avg 29.1x at the last 3 fiscal year-ends).
- 3 of 80 tracked superinvestors hold CAH (13F, Q2 2026): 0 new, 1 added, 0 reduced, 2 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $59.6M; 7 not under a Rule 10b5-1 plan ($59.6M); 1 by opportunistic insiders (1 outside 10b5-1 plans), 3 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (17 analysts), mean target USD 273.47 (range 235–295).
- Total return with dividends: 1Y +62.1% vs S&P 500 +14.9%; 5Y +470.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.94, revenue estimate $66.5B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CAH)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $181B | $205B | $227B | $223B | $254B | $245B |
| Gross profit | $6.48B | $6.87B | $7.41B | $8.17B | $9.77B | — |
| Operating income | -$607M | $752M | $1.24B | $2.27B | $2.61B | $2.53B |
| Net income | -$938M | $330M | $852M | $1.56B | $1.71B | $1.66B |
| EPS (diluted) | -$3.37 | $1.26 | $3.45 | $6.45 | $7.23 | — |
| Free cash flow | $2.79B | $2.36B | $3.25B | $1.85B | $4.53B | $5.50B |
| Gross margin | 3.6% | 3.4% | 3.3% | 3.7% | 3.8% | — |
| Operating margin | -0.3% | 0.4% | 0.5% | 1.0% | 1.0% | 1.0% |
| Net margin | -0.5% | 0.2% | 0.4% | 0.7% | 0.7% | 0.7% |
| Revenue growth | +11.6% | +13.0% | +10.7% | -1.9% | +14.2% | — |
| Cash + short-term investments | $4.72B | $4.08B | $5.33B | — | — | — |
| Total debt | $5.30B | $4.70B | $5.10B | $8.53B | $7.00B | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Dec 31, 2025) (CAH)
P/E 35.6x · P/S 0.2x · P/FCF 10.8x · FCF yield 9.29% · Earnings yield 2.81% · Dividend yield (paid, TTM) 0.84% · Buyback yield (TTM) 1.91%
P/E at fiscal year-ends: Jun 2026 32.8x, Jun 2025 26.0x, Jun 2024 28.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (CAH)
3 of 80 tracked investors hold CAH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Mason Hawkins | Southeastern Asset Management | 0.09% | $1.7M | Unchanged |
| First Eagle Investment | First Eagle Investment Management | <0.01% | $1.4M | Added +1.7% |
| Mairs & Power | Mairs & Power Funds | <0.01% | $504K | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (CAH)
0 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Scherer Mary C. | Chief Accounting Officer | 2,302 | $546K | 45% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-18…2026-08-19 | Hollar Jason M. | Chief Executive Officer | 124,529 | $29.4M | 39.5% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Mason Stephen M | CEO, GMPD Segment | 35,000 | $8.3M | 66% | No | Routine (sold in Aug each year 2023–2025) |
| 2026-08-18 | Weitzman Deborah | CEO, PSS Segment | 7,354 | $1.7M | 8.6% | No | Too little history (no open-market trades in 2024) |
| 2026-08-18 | Alt Aaron E | Chief Financial Officer | 42,000 | $9.9M | 67.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Mayer Jessica L | Chief Legal/Compliance Officer | 29,436 | $7.0M | 47.1% | No | Routine (sold in Aug each year 2023–2025) |
| 2026-08-18 | Greene Michelle D. | Chief Information Officer | 11,650 | $2.7M | 53% | No | Routine (sold in Aug each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CAH)
Consensus Buy (mean 2.00 on a 1–5 scale), 17 analysts; mean target USD 273.47 (low 235, high 295).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Mizuho | Target raised | Outperform | $250 → $280 |
| 2026-10-16 | UBS | Target raised | Buy | $280 → $295 |
| 2026-08-19 | RBC Capital | Initiated | Outperform | $276 |
| 2026-08-13 | TD Cowen | Target raised | Buy | $275 → $280 |
| 2026-08-13 | JP Morgan | Target raised | Neutral | $215 → $260 |
| 2026-08-13 | Barclays | Target raised | Overweight | $258 → $275 |
| 2026-08-12 | Citigroup | Target raised | Buy | $265 → $280 |
| 2026-08-12 | Evercore ISI Group | Target raised | Outperform | $265 → $270 |
| 2026-08-12 | Morgan Stanley | Target raised | Overweight | $255 → $265 |
| 2026-08-12 | Mizuho | Target raised | Outperform | $240 → $250 |
| 2026-08-12 | UBS | Target raised | Buy | $274 → $280 |
| 2026-08-12 | Wells Fargo | Target raised | Overweight | $245 → $277 |
Total return (dividends reinvested) (CAH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +62.1% | +470.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +62.4% | +41.6% |
| Volatility (annualized) | 29.1% | 24.6% |
| Max drawdown | -20.4% (Mar 2026→May 2026) | -19.7% (Feb 2026→May 2026) |
Companies that name CAH in their SEC reports
| Relationship to CAH | Company | Filing | Sentence |
|---|---|---|---|
| supplier | TAKEDA PHARMACEUTICAL CO LTD (TAK) | 20-F Jun 17, 2026 | “The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.” |
| competitor | MCKESSON CORP (MCK) | 10-K May 8, 2026 | “Our primary competitors in distribution, wholesaling, and logistics are Cencora, Inc. and Cardinal Health, Inc.” |
| supplier | Scilex Holding Co (SCLX) | 10-K Apr 10, 2026 | “Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, LLC ("Cardinal Health 105"), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours.” |
| supplier | Jaguar Health, Inc. (JAGX) | 10-K Apr 7, 2026 | “For contracts with Cardinal Health, a single performance obligation is satisfied at a point in time upon each contract's Free On Board ("FOB") terms when control, including title and all risks, has transferred to the customer.” |
| partner | Autolus Therapeutics plc (AUTL) | 10-K Mar 27, 2026 | “We intend for the Nucleus to meet the global supply demands of AUCATZYL, with Cardinal Health 105, LLC serving as our commercial distribution partner in the US.” |
| partner | bioAffinity Technologies, Inc. (BIAF) | 10-K Mar 16, 2026 | “have an agreement with Cardinal Health for logistical services assisting in the delivery of collection kits and” |
| competitor | ALPHA PRO TECH LTD (APT) | 10-K Mar 11, 2026 | “Other large competitors include 3M Company, Johnson & Johnson, White Knight Engineered Products (Precept Medical Products, Inc.), Cardinal Health, Inc. and Medline Industries Inc. Our major competitors in the industrial and cleanroom market are our former largest distributor, VWR International, LLC, Kimberly-Clark Corporation, 3M Company, Kappler, Inc., DuPont and Allegiance Healthcare Corporation.” |
| supplier | CUMBERLAND PHARMACEUTICALS INC (CPIX) | 10-K Mar 9, 2026 | “In 2025, Cardinal Health Specialty Solutions exclusively handled our U.S. product logistics activities, including warehousing, shipping, and various other customer activities.” |
| supplier | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | 10-K Mar 2, 2026 | “Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76% of our total product revenue in 2025.” |
| competitor | Solventum Corp (SOLV) | 10-K Feb 27, 2026 | “Our principal competitors in this segment include Becton Dickinson, Hartmann, ICU Medical, Medline, Cardinal Health, Fortive, Steris, MDF Instruments, and BSN.” |
| supplier | Butterfly Network, Inc. (BFLY) | 10-K Feb 27, 2026 | “Under the Distribution Agreement, Cardinal Health acts as the distribution agent and authorized distributor of record of our products to our customers, including, but not limited to, wholesalers, specialty distributors, physicians, clinics, hospitals, pharmacies and other healthcare providers, in the United States.” |
| supplier | Amneal Pharmaceuticals, Inc. (AMRX) | 10-K Feb 27, 2026 | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| customer | Medline Inc. (MDLN) | 10-K Feb 25, 2026 | “Additionally, other distributors of med-surg products similarly connect the fragmented supplier and provider bases and aggregate inventory from suppliers to deliver products to customers, such as McKesson, Cardinal Health, Owens & Minor, and Henry Schein.” |
| supplier | Merck & Co., Inc. (MRK) | 10-K Feb 24, 2026 | “The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.” |
| competitor | AdaptHealth Corp. (AHCO) | 10-K Feb 24, 2026 | “AdaptHealth competes with other large national providers, including Accendra Health, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc. and Quipt Home Medical Corp; regional providers, including DASCO Home Medical Equipment, Binson's Medical Equipment, Inc., Norco, Inc., Protech Home Medical Corp., and Viemed Healthcare, Inc.; and product-specific providers, including Breg, Inc., Inogen, Inc., A…” |
CAH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.94 | $2.90 | +1.3% | $66.51B | 13 |
| Next quarter (ends Dec 2026) | $3.13 | $2.99 | +4.8% | $68.29B | 13 |
| Current fiscal year (ends Jun 2027) | $12.56 | $12.06 | +4.1% | $265.77B | 17 |
| Next fiscal year (ends Jun 2028) | $14.06 | $13.55 | +3.7% | $281.85B | 17 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 255.64 |
|---|---|
| Change | ▼ 0.71% (down) |
| Previous Close | USD 257.46 |
| Open | USD 258.21 |
| Day Range | USD 254.85 – 259.21 |
| 52-Week Range | USD 158.7 – 259.21 |
| Volume | 1,497,509 shares |
| Market Cap | $59.20B |
| Exchange | NYQ |
Technical Analysis (CAH)
Nexqual's technical model rates CAH "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.05 (neutral) |
| vs SMA50 | Above (USD 235.9) |
| MACD | 6.84 (positive) |
Analyst Ratings (CAH)
Wall Street analysts rate CAH "Buy" based on 17 analysts, with a mean price target of USD 273.47 (range USD 235–295), per Nexqual as of October 23, 2026 at 09:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 273.47 |
| High Target | USD 295 |
| Low Target | USD 235 |
| Buy / Hold / Sell | 14 / 3 / 0 |
Earnings (CAH)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.94 |
| Revenue Estimate | $66.51B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.6 vs est 2.42 ▲ beat |
| 2026-03-31 | USD 3.17 vs est 2.79 ▲ beat |
| 2025-12-31 | USD 2.63 vs est 2.37 ▲ beat |
| 2025-09-30 | USD 2.55 vs est 2.17 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (CAH)
| Total Revenue | $254.25B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.80% |
| Gross Margin | +3.84% |
| Operating Margin | +1.33% |
| Profit Margin | +0.67% |
| Current Ratio | 0.88 |
| Total Cash | $4.86B |
| Total Debt | $10.00B |
| Free Cash Flow (last four quarters to Dec 2025, SEC 10-Q / 10-K) | $5.50B (2.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financial Health Score (CAH)
Nexqual rates Cardinal Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:27 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 1% (last 12 months) |
| Balance Sheet | Mixed — $4.86B cash vs $10.00B debt |
| Cash Flow | Mixed — FCF $5.50B (last 4 quarters to Dec 2025, SEC), slim 2.2% margin |
| Efficiency | Mixed — No data |
Ownership (CAH)
| Insider Ownership | +0.28% |
|---|---|
| Institutional Ownership | +91.41% |
| Shares Outstanding | 231.56M |
| Float | 232.04M |
| Short % of Float | +3.18% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Leadership (CAH)
Cardinal Health, Inc. is led by Jason M. Hollar, CEO & Director, per Nexqual as of October 23, 2026 at 09:27 UTC.
| CEO & Director | Jason M. Hollar |
|---|---|
| Chief Financial Officer | Aaron E. Alt |
| Vice President of Investor Relations | David Frost |
| President of Biopharma Solutions & Strategic Sourcing | Craig Cowman |
| President of Global Operations & Supply Chain | Ben Brinker |
Major Backers & Investors (CAH)
Notable institutional backers of Cardinal Health, Inc. include Wellington Management, Invesco, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.42% |
| Invesco | 2.05% |
| Morgan Stanley | 2% |
| WCM Investment Management, LLC | 1.78% |
| NORGES BANK | 1.61% |
| Fidelity | 1.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.52% |
| BlackRock | 11.44% |
| State Street | 5.17% |
| Geode Capital | 2.8% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COR | Cencora, Inc. | USD 338.48 | ▼ 0.57% |
| MCK | McKesson Corporation | USD 1,012.34 | ▼ 0.31% |
| HSIC | Henry Schein, Inc. | USD 86 | ▲ 1.16% |
| AHG | Akso Health Group | USD 1.22 | ▼ 3.94% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt